GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DARA Biosciences Inc (NAS:DARA) » Definitions » Cyclically Adjusted Book per Share

DARA Biosciences (DARA Biosciences) Cyclically Adjusted Book per Share : $0.00 (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is DARA Biosciences Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

DARA Biosciences's adjusted book value per share for the three months ended in Sep. 2015 was $0.312. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Sep. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-05), DARA Biosciences's current stock price is $0.88. DARA Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2015 was $0.00. DARA Biosciences's Cyclically Adjusted PB Ratio of today is .


DARA Biosciences Cyclically Adjusted Book per Share Historical Data

The historical data trend for DARA Biosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DARA Biosciences Cyclically Adjusted Book per Share Chart

DARA Biosciences Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DARA Biosciences Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DARA Biosciences's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, DARA Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DARA Biosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DARA Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where DARA Biosciences's Cyclically Adjusted PB Ratio falls into.



DARA Biosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DARA Biosciences's adjusted Book Value per Share data for the three months ended in Sep. 2015 was:

Adj_Book= Book Value per Share /CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=0.312/100.3915*100.3915
=0.312

Current CPI (Sep. 2015) = 100.3915.

DARA Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
200512 4,686.512 83.032 5,666.321
200603 2,646.777 84.298 3,152.086
200606 2,062.012 85.606 2,418.162
200609 1,345.605 85.606 1,578.018
200612 776.465 85.142 915.539
200703 591.042 86.640 684.851
200706 338.436 87.906 386.505
200709 125.733 87.964 143.496
200712 586.238 88.616 664.136
200803 16.255 90.090 18.114
200806 12.883 92.320 14.009
200809 3.447 92.307 3.749
200812 4.621 88.697 5.230
200903 -2.378 89.744 -2.660
200906 -0.714 91.003 -0.788
200909 4.613 91.120 5.082
200912 4.881 91.111 5.378
201003 6.076 91.821 6.643
201006 3.015 91.962 3.291
201009 0.446 92.162 0.486
201012 6.188 92.474 6.718
201103 4.791 94.283 5.101
201106 3.055 95.235 3.220
201109 2.185 95.727 2.291
201112 1.048 95.213 1.105
201203 2.673 96.783 2.773
201206 5.371 96.819 5.569
201209 3.202 97.633 3.292
201212 2.543 96.871 2.635
201303 2.224 98.209 2.273
201306 1.765 98.518 1.799
201309 1.265 98.790 1.286
201312 1.067 98.326 1.089
201403 1.159 99.695 1.167
201406 0.970 100.560 0.968
201409 0.852 100.428 0.852
201412 0.704 99.070 0.713
201503 0.564 99.621 0.568
201506 0.440 100.684 0.439
201509 0.312 100.392 0.312

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


DARA Biosciences  (NAS:DARA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


DARA Biosciences Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of DARA Biosciences's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


DARA Biosciences (DARA Biosciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Executives
David Drutz director, officer: Executive Chairman and CMO 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David L. Tousley officer: CFO 14610 PAWNEE LANE, LEAWOOD KS 66224
Gail Lieberman director 175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075
Paul John Richardson director 17 COUNTRY OAKS ROAD, LEBANON NJ 08833
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Ann A Rosar officer: Vice President Finance C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Geert Cauwenbergh director 1 STULTS DRIVE, PLAINSBORO NJ 08536
Kurt M Eichler director C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757
Hamilton Jordan director
Stuart C Mcwhorter director 113 SEABOARD LANE, FRANKLIN TN 37067
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Michael P Duffy officer: SVP, GC and Secretary C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110
Richard J Benjamin director 15 WHITE PINE ROAD, NEWTON MA 02464
Larry G Pickering director 26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134

DARA Biosciences (DARA Biosciences) Headlines